1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Quviviq |
| structure | File | |
| classes | List of String, delimiter: , | Dual orexin receptor antagonist (DORA) |
| mechanism | String | |
| uses | String | Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) |
| starting_dose | String | 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate |
| preparations | String | 25 mg, 50 mg tablets |
| fda_max | String | 50 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | ~30 min |
| duration | String | ~7-8 hours |
| halflife | String | ~8 hours (shorter than suvorexant and lemborexant) |
| bioavailability | String | ~62% |
| pregnancy | String | Limited data; avoid |
| legal | String | Rx, Schedule IV (US) |
